Medical Affairs Pfizer Colombia, Colombia; Foundation For Development And Support In International Health (FUDASAI), Miami, FL, USA.
Medical Affairs Pfizer Colombia, Colombia.
Diagn Microbiol Infect Dis. 2024 Jun;109(2):116235. doi: 10.1016/j.diagmicrobio.2024.116235. Epub 2024 Feb 29.
Ceftazidime-avibactam (CAZ-AVI) is an option for infections caused by MDR gram-negative bacilli. In this study, we aimed to analyze the in vitro antimicrobial activity of CAZ-AVI and other antimicrobial agents against gram-negative bacilli that were collected in Colombia between 2019 and 2021 from patients with bacteremia and skin and soft-tissue infections (SSTIs).
A total of 600 Enterobacterales and 259 P. aeruginosa strains were analyzed. The phenotypic resistance of isolates, particularly non-susceptibility to meropenem, multidrug-resistant (MDR) isolates, and difficult-to-treat (DTR) P. aeruginosa, was evaluated according to CLSI breakpoints.
Enterobacterales had the most susceptibility to CAZ-AVI (96.5 %) and tigecycline (95 %). Tigecycline and CAZ-AVI were the antimicrobial agents with the most in vitro activity against carbapenem-resistant Enterobacterales (CRE). CAZ-AVI was the antimicrobial treatment with the most activity against P. aeruginosa.
Tigecycline and CAZ-AVI were the antimicrobial agents with the most activity against CRE and MDR Enterobacterales. For P. aeruginosa, CAZ-AVI was the antimicrobial treatment with the most in vitro activity.
头孢他啶-阿维巴坦（CAZ-AVI）是治疗多重耐药革兰氏阴性杆菌引起感染的一种选择。本研究旨在分析 CAZ-AVI 和其他抗菌药物对 2019 年至 2021 年期间哥伦比亚从菌血症和皮肤软组织感染（SSTI）患者中分离的革兰氏阴性杆菌的体外抗菌活性。
共分析了 600 株肠杆菌科和 259 株铜绿假单胞菌。根据 CLSI 折点评估分离株的表型耐药性，特别是对美罗培南的非敏感性、多重耐药（MDR）分离株和治疗困难（DTR）的铜绿假单胞菌。
肠杆菌科对 CAZ-AVI（96.5%）和替加环素（95%）的敏感性最高。替加环素和 CAZ-AVI 是对碳青霉烯类耐药肠杆菌科（CRE）具有最强体外活性的抗菌药物。CAZ-AVI 是对铜绿假单胞菌最有效的抗菌治疗药物。
替加环素和 CAZ-AVI 是对 CRE 和 MDR 肠杆菌科最有效的抗菌药物。对于铜绿假单胞菌，CAZ-AVI 是体外活性最强的抗菌治疗药物。
